Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein

mAbs

Volumn 4, Issue 2, 2012, Pages 233-242

  Chatterjee, Deboeeta ^a   Chandran, Bala ^b   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Ganciclovir; Human herpesvirus 8; KSHV lytic infection; KSHV surface glycoprotein; Multicentric Castleman disease; Pseudomonas exotoxin A; Reciprocal drug potentiation; Targeted cytotoxic proteins

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; GLYCOPROTEIN GPK8.1A; IMMUNOTOXIN; RECOMBINANT IMMUNOTOXIN 2014 PE38; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; GLYCOPROTEIN; K8.1 PROTEIN, HUMAN HERPESVIRUS 8; RECOMBINANT PROTEIN; VIRUS ANTIBODY; VIRUS PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL SURFACE; CONCENTRATION RESPONSE; CYTOLYSIS; DNA REPLICATION; DRUG DESIGN; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; HUMAN HERPESVIRUS 8; NONHUMAN; NUCLEOTIDE SEQUENCE; VERO CELL; VIRION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; GENETICS; HERPESVIRIDAE INFECTIONS; HUMAN; IMMUNOLOGY; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; VERO CELL LINE; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; DNA REPLICATION; DNA, VIRAL; GLYCOPROTEINS; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOTOXINS; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; VERO CELLS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84858266126     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.4.2.19262     Document Type: Article

References (95)

1. Ganem D. Kaposi's sarcoma-associated herpesvirus. In: Knipe DM, Howley PM, Eds. Fields Virology. Philadelphia, PA: Lippincott Williams and Wilkins 2007; 5:2847-88.
2. Pellett PE, Roizman B. The family Herpesviridae: a brief introduction. In: Knipe DM, Howley PM, Eds. Fields Virology, Fifth Edition. Philadelphia: Lipincott Williams & Wilkens 2007; 2479-99.
3. Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010; 289:140-50; PMID:19651473; http://dx.doi.org/10.1016/j.canlet.2009.07.004.
4. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9; PMID:7997879; http://dx.doi.org/10.1126/ science.7997879.
5. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-91; PMID:7700311; http://dx.doi.org/10.1056/NEJM199505043321802.
6. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276-80; PMID:7632932.
7. Moore PS, Chang Y. Kaposi?s sarcoma-associated herpesvirus immunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol 2003; 57:609-39; PMID:14527293; http://dx.doi.org/10.1146/annurev.micro.57.030502. 090824.
8. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. HIV/AIDS: epidemiology, pathophysiology and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma and multicentric Castleman disease. Clin Infect Dis 2008; 47:1209-15; PMID:18808357; http://dx.doi.org/10.1086/592298.
9. Gantt S, Casper C. Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment. Curr Opin Infect Dis 2011; 24:295-301; PMID:21666458; http://dx.doi.org/10.1097/QCO.0b013e3283486d04.
10. Cesarman E. Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 2011; 305:163-74; PMID:21493001; http://dx.doi.org/10.1016/j.canlet.2011.03.003.
11. Katano H, Sato Y, Kurata T, Mori S, Sata T. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma and multicentric Castleman?s disease. Virology 2000; 269:335-44; PMID:10753712; http://dx.doi.org/10.1006/viro.2000.0196.
12. Parravicini C, Chandran B, Corbellino M, Berti E, Paulli M, Moore PS, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi?s sarcoma, primary effusion lymphoma and multicentric Castleman's disease. Am J Pathol 2000; 156:743-9; PMID:10702388; http://dx.doi.org/10.1016/S0002-9440(10)64940-1.
13. Asahi-Ozaki Y, Sato Y, Kanno T, Sata T, Katano H. Quantitative analysis of Kaposi sarcoma-associated herpesvirus (KSHV) in KSHV-associated diseases. J Infect Dis 2006; 193:773-82; PMID:16479510; http://dx.doi.org/10.1086/500560.
14. Burbelo PD, Issa AT, Ching KH, Wyvill KM, Little RF, Iadarola MJ, et al. Distinct profiles of antibodies to Kaposi sarcoma-associated herpesvirus antigens in patients with Kaposi sarcoma, multicentric Castleman disease and primary effusion lymphoma. J Infect Dis 2010; 201:1919-22; PMID:20443737; http://dx.doi.org/10.1086/652869.
15. Stebbing J, Pantanowitz L, Dayyani F, Sullivan RJ, Bower M, Dezube BJ. HIV-associated multicentric Castleman's disease. Am J Hematol 2008; 83:498-503; PMID:18260115; http://dx.doi.org/10.1002/ajh.21137.
16. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009; 4:16-21; PMID:19343828; http://dx.doi.org/10.1097/COH. 0b013e328319bca9.
17. Cronin DMP, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16:236-46; PMID:19546611; http://dx.doi.org/10.1097/PAP.0b013e3181a9d4d3.
18. Bower M, Newsom-Davis T, Naresh K, Merchant S, Lee B, Gazzard B, et al. Clinical features and outcome in HIV-associated multicentric Castleman's disease. J Clin Oncol 2011; 29:2481-6; PMID:21555697; http://dx.doi.org/10.1200/ JCO.2010.34.1909.
19. Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin- 10 and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069-73; PMID:10979949.
20. Stebbing J, Adams C, Sanitt A, Mletzko S, Nelson M, Gazzard B, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood 2011; 118:271-5; PMID:21511959; http://dx.doi.org/10. 1182/blood-2011-02-335620.
21. Dittmer DP, Vahrson W, Staudt M, Hilscher C, Fakhari FD. Kaposi's sarcoma in the era of HAART-an update on mechanisms, diagnostics and treatment. AIDS Rev 2005; 7:56-61; PMID:15875661.
22. Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009; 20:775-9; PMID:19179554; http://dx.doi.org/10.1093/annonc/mdn697.
23. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10:25-35; PMID:18385778.
24. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010; 116:4415-21; PMID:20688959; http://dx.doi.org/10.1182/blood-2010-07- 290213.
25. El-Osta HE, Kurzrock R. Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist 2011; 16:497-511; PMID:21441298; http://dx.doi.org/10.1634/theoncologist.2010-0212.
26. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007; 46:771-4; PMID:17541233; http://dx.doi.org/10.2169/internalmedicine.46.6262.
27. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin- 6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010; 28:3701-8; PMID:20625121; http://dx.doi.org/10.1200/ JCO.2009.27.2377.
28. G?rard L, B?rezn? A, Galicier L, Meignin V, Obadia M, De Castro N, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25:3350-6; PMID:17664482; http://dx.doi.org/10.1200/JCO.2007. 10.6732.
29. Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147:836-9; PMID:18087054.
30. Bestawros A, Michel R, S?guin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series. Am J Hematol 2008; 83:508-11; PMID:18027834; http://dx.doi.org/10.1002/ajh.21108.
31. Schmidt SM, Raible A, Kort?m F, Mayer F, Riessen R, Adam P, et al. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia 2008; 22:1782-5; PMID:18449205; http://dx.doi.org/10.1038/leu.2008.54.
32. Law AB, Ryan G, Lade S, Prince HM. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol 2010; 91:347-8; PMID:20146033; http://dx.doi.org/10.1007/s12185-010-0497-9.
33. Yuan ZG, Dun XY, Li YH, Hou J. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol 2009; 2:19; PMID:19400935; http://dx.doi.org/10.1186/1756-8722-2-19.
34. Casper C, Nichols WG, Huang ML, Corey L, Wald A. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-4; PMID:14615380; http://dx.doi.org/10.1182/blood-2003-05-1721.
35. Uldrick TS, Polizzotto MN, Aleman K, O'Mahony D, Wyvill KM, Wang V, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood 2011; 117:6977-86; PMID:21487108; http://dx.doi.org/10.1182/blood-2010-11-317610.
36. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011; 34:611-28; PMID:21989410; http://dx.doi.org/10.1097/CJI.0b013e318234ecf5.
37. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010; 14:529-37; PMID:20643572; http://dx.doi.org/10.1016/j.cbpa.2010.06.170.
38. Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011; 17:6389-97; PMID:22003066; http://dx.doi.org/ 10.1158/1078-0432.CCR-11-1417.
39. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy 2011; 3:349-70; PMID:21395378; http://dx.doi.org/10.2217/imt.10.114.
40. Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res 2011; 17:6406-16; PMID:22003068; http://dx.doi.org/10.1158/1078-0432.CCR-11-0483.
41. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med 2007; 58:221-37; PMID:17059365; http://dx.doi.org/10.1146/ annurev.med.58.070605.115320.
42. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011; 16:495-503; PMID:21511052; http://dx.doi.org/10.1016/j.drudis.2011.04.003.
43. Berger EA. Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs. Curr Opin HIV AIDS 2011; 6:80-5; PMID:21242898; http://dx.doi.org/10.1097/COH. 0b013e3283412515.
44. Johansson S, Goldenberg DM, Griffiths GL, Wahren B, Hinkula J. Elimination of HIV-1 infection by treatment with a doxorubicin-conjugated anti-envelope antibody. AIDS 2006; 20:1911-5; PMID:16988511; http://dx.doi.org/10.1097/01.aids.0000247111.58961.60.
45. Dadachova E, Casadevall A. Radioimmunotherapy of infectious diseases. Semin Nucl Med 2009; 39:146-53; PMID:19187806; http://dx.doi.org/10.1053/j. semnuclmed. 2008.10.007.
46. Barnett BB, Burns NJ, 3rd, Park KJ, Dawson MI, Kende M, Sidwell RW. Antiviral immunotoxins: antibody- mediated delivery of gelonin inhibits Pichinde virus replication in vitro. Antiviral Res 1991; 15:125-38; PMID:1650165; http://dx.doi.org/10.1016/0166-3542(91)90030-U.
47. Barnett BB, Smee DF, Malek SM, Sidwell RW. Selective cytotoxicity towards cytomegalovirus-infected cells by immunotoxins consisting of gelonin linked to anti-cytomegalovirus antibody. Antiviral Res 1995; 28:93-100; PMID:8585763; http://dx.doi.org/10.1016/0166-3542(95)00034-J.
48. Barnett BB, Smee DF, Malek SM, Sidwell RW. Selective cytotoxicity of ricin A chain immunotoxins towards murine cytomegalovirus-infected cells. Antimicrob Agents Chemother 1996; 40:470-2; PMID:8834901.
49. Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 2010; 6:1000803; PMID:20548940; http://dx.doi.org/10.1371/journal.ppat.1000803.
50. Mareeva T, Wanjalla C, Schnell MJ, Sykulev Y. A novel composite immunotoxin that suppresses rabies virus production by the infected cells. J Immunol Methods 2010; 353:78-86; PMID:19932697; http://dx.doi.org/10.1016/j.jim. 2009.11.010.
51. Chandran B. Early events in Kaposi?s sarcoma-associated herpesvirus infection of target cells. J Virol 2010; 84:2188-99; PMID:19923183; http://dx.doi.org/10.1128/JVI.01334-09.
52. Chandran B, Bloomer C, Chan SR, Zhu LJ, Goldstein E, Horvat R. Human herpesvirus-8 ORF K8.1 gene encodes immunogenic glycoproteins generated by spliced transcripts. Virology 1998; 249:140-9; PMID:9740785; http://dx.doi.org/10.1006/viro.1998.9316.
53. Li MT, MacKey J, Czajak SC, Desrosiers RC, Lackner AA, Jung JU. Identification and characterization of Kaposi?s sarcoma-associated herpesvirus K8.1 virion glycoprotein. J Virol 1999; 73:1341-9; PMID:9882339.
54. Wu LJ, Renne R, Ganem D, Forghani B. Human herpesvirus 8 glycoprotein K8.1: expression, post-translational modification and localization analyzed by monoclonal antibody. J Clin Virol 2000; 17:127-36; PMID:10942093; http://dx.doi.org/10.1016/S1386-6532(00)00085-8.
55. Zhu LJ, Puri V, Chandran B. Characterization of human herpesvirus-8 K8.1A/B glycoproteins by monoclonal antibodies. Virology 1999; 262:237-49; PMID:10489357; http://dx.doi.org/10.1006/viro.1999.9900.
56. Zhu FX, Chong JM, Wu LJ, Yuan Y. Virion proteins of Kaposi?s sarcoma-associated herpesvirus. J Virol 2005; 79:800-11; PMID:15613308; http://dx.doi.org/10.1128/JVI.79.2.800-11.2005.
57. Wang FZ, Akula SM, Pramod NP, Zeng L, Chandran B. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J Virol 2001; 75:7517-27; PMID:11462024; http://dx.doi.org/10.1128/JVI. 75.16.7517-27.2001.
58. Birkmann A, Mahr K, Ensser A, Yaubolu S, Titgemeyer F, Fleckenstein B, et al. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol 2001; 75:11583-93; PMID:11689640; http://dx.doi.org/10.1128/JVI.75.23.11583-93.2001.
59. Engels EA, Whitby D, Goebel PB, Stossel A, Waters D, Pintus A, et al. Identifying human herpesvirus 8 infection: performance characteristics of serologic assays. J Acquir Immune Defic Syndr 2000; 23:346-54; PMID:10836758.
60. Zoeteweij JP, Eyes ST, Orenstein JM, Kawamura T, Wu LJ, Chandran B, et al. Identification and rapid quantification of early- and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. J Virol 1999; 73:5894-902; PMID:10364341.
61. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. In: Lo BKC, Ed. Meth Molec Biol. Totowa, NJ: Humana Press Inc. 2003; 503-18.
62. Vieira J, O'Hearn PM. Use of the red fluorescent protein as a marker of Kaposi?s sarcoma-associated herpesvirus lytic gene expression. Virology 2004; 325:225-40; PMID:15246263; http://dx.doi.org/10.1016/j.virol.2004.03.049.
63. Tominaga H, Ishiyama M, Ohseto F, Sasamoto K, Hamamoto T, Suzuki K, et al. A water-soluble tetrazolium salt useful for colorimetric cell viability assay. Anal Commun 1999; 36:47-50; http://dx.doi.org/10.1039/a809656b.
64. Kedes DH, Ganem D. Sensitivity of Kaposi?s sarcoma- associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 1997; 99:2082-6; PMID:9151779; http://dx.doi.org/10.1172/ JCI119380.
65. Medveczky MM, Horvath E, Lund T, Medveczky PG. In vitro antiviral drug sensitivity of the Kaposi?s sarcoma-associated herpesvirus. AIDS 1997; 11:1327-32; PMID:9302441; http://dx.doi.org/10.1097/00002030-199711000-00006.
66. Lu M, Suen J, Frias C, Pfeiffer R, Tsai MH, Chuang E, et al. Dissection of the Kaposi?s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol 2004; 78:13637-52; PMID:15564474; http://dx.doi.org/10.1128/JVI.78.24.13637-52.2004.
67. Casper C, Krantz EM, Corey L, Kuntz SR, Wang J, Selke S, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double- blind, placebo-controlled, crossover trial. J Infect Dis 2008; 198:23-30; PMID:18491970; http://dx.doi.org/10.1086/588820.
68. Cattamanchi A, Saracino M, Selke S, Huang ML, Magaret A, Celum C, et al. Treatment with valacyclovir, famciclovir or antiretrovirals reduces human herpes-virus- 8 replication in HIV-1 seropositive men. J Med Virol 2011; 83:1696-703; PMID:21837785; http://dx.doi.org/10.1002/jmv.22194.
69. Ashorn P, Englund G, Martin MA, Moss B, Berger EA. Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages. J Infect Dis 1991; 163:703-9; PMID:2010626; http://dx.doi.org/10.1093/infdis/163.4.703.
70. Kennedy PE, Bera TK, Wang QC, Gallo M, Wagner W, Lewis MG, et al. Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages and negligible hepatotoxicity in macaques. J Leukoc Biol 2006; 80:1175-82; PMID:16923920; http://dx.doi.org/10.1189/jlb. 0306139.
71. Potts BJ, Maury W, Martin MA. Replication of HIV-1 in primary monocyte cultures. Virology 1990; 175:465-76; PMID:2183468; http://dx.doi.org/10.1016/ 0042-6822(90)90431-P.
72. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian and pancreatic cancers. Clin Cancer Res 2007; 13:5144-9; PMID:17785569; http://dx.doi.org/10.1158/1078-0432.CCR-07-0869.
73. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I/II trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol; In press.
74. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJP, Wilson WH, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 2005; 23:6719-29; PMID:16061911; http://dx.doi.org/10.1200/JCO.2005.11.437.
75. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011; 17:6398-405; PMID:22003067; http://dx.doi.org/10.1158/1078-0432.CCR-11-0487.
76. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-9; PMID:15155471; http://dx.doi.org/10.1182/blood-2004-01-0158.
77. Cai Y, Berger EA. An immunotoxin targeting the gH glycoprotein of KSHV for selective killing of cells in the lytic phase of infection. Antiviral Res 2011; 90:143-50; PMID:21440007; http://dx.doi.org/10.1016/j.antiviral. 2011.03.175.
78. Smee DF, Sidwell RW, Barnett BB. Combination of antiviral immunotoxin and ganciclovir or cidofovir for the treatment of murine cytomegalovirus infections. Antiviral Res 1996; 32:165-71; PMID:8955511; http://dx.doi.org/10. 1016/S0166-3542(95)00986-8.
79. Ashorn P, Moss B, Weinstein JN, Chaudhary VK, FitzGerald DJ, Pastan I, et al. Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1990; 87:8889-93; PMID:1701055; http://dx.doi.org/10.1073/pnas.87.22.8889.
80. Tsubota H, Winkler G, Meade HM, Jakubowski A, Thomas DW, Letvin NL. CD4-Pseudomonas exotoxin conjugates delay but do not fully inhibit human immunodeficiency virus replication in lymphocytes in vitro. J Clin Invest 1990; 86:1684-9; PMID:2243139; http://dx.doi.org/10.1172/JCI114892.
81. Goldstein H, Pettoello-Mantovani M, Bera TK, Pastan IH, Berger EA. Chimeric toxins targeted to the human immunodeficiency virus type 1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. J Infect Dis 2000; 181:921-6; PMID:10720513; http://dx.doi.org/10.1086/315351.
82. Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009; 9:1445-51; PMID:19817678; http://dx.doi.org/10.1517/ 14712590903348135.
83. Woo JH, Frankel A, Neville DM. Cytotoxic therapy with diphtheria toxin fusion proteins. Drugs Future 2010; 35:823-31; http://dx.doi.org/10.1358/dof. 2010.035.010.1534010.
84. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17:6417-27; PMID:22003069; http://dx.doi.org/10.1158/1078-0432.CCR-11-0486.
85. Hetzel C, Bachran C, Tur MK, Fuchs H, Stöcker M. Improved immunotoxins with novel functional elements. Curr Pharm Des 2009; 15:2700-11; PMID:19689340; http://dx.doi.org/10.2174/138161209788923930.
86. Weldon JE, Pastan I. A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011; 278:4683-700; PMID:21585657; http://dx.doi.org/10.1111/j.1742-4658.2011. 08182.x.
87. Bera TK, Pastan I. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size and stability. Bioconjug Chem 1998; 9:736-43; PMID:9815167; http://dx.doi.org/10.1021/ bc980028o.
88. Hakim R, Benhar I. ?Inclonals?: IgGs and IgG-enzyme fusion proteins produced in an E. coli expression-refolding system. MAbs 2009; 1:281-7; PMID:20065645; http://dx.doi.org/10.4161/mabs.1.3.8492.
89. Onda M, Beers R, Xiang LM, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci USA 2011; 108:5742-7; PMID:21436054; http://dx.doi.org/10.1073/pnas.1102746108.
90. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009; 100:1359-65; PMID:19459847; http://dx.doi.org/10.1111/j.1349-7006.2009.01192.x.
91. Lorberboum-Galski H. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases. Expert Opin Drug Deliv 2011; 8:605-21; PMID:21453191; http://dx.doi.org/10.1517/ 17425247.2011.566269.
92. Bera TK, Kennedy PE, Berger EA, Barbas CFI, 3rd, Pastan I. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein. Mol Med 1998; 4:384-91; PMID:10780881.
93. Douglas CM, Collier RJ. Exotoxin A of Pseudomonas aeruginosa: substitution of glutamic acid 553 with aspartic acid drastically reduces toxicity and enzymatic activity. J Bacteriol 1987; 169:4967-71; PMID:2889718.
94. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 2001; 345:241-7; PMID:11474661; http://dx.doi.org/10.1056/NEJM200107263450402.
95. Dube D, Schornberg KL, Shoemaker CJ, Delos SE, Stantchev TS, Clouse KA, et al. Cell adhesion-dependent membrane trafficking of a binding partner for the ebolavirus glycoprotein is a determinant of viral entry. Proc Natl Acad Sci USA 2010; 107:16637-42; PMID:20817853; http://dx.doi.org/10.1073/pnas.1008509107.